Danaher price target lowered to $260 from $270 at Barclays

Barclays lowered the firm’s price target on Danaher to $260 from $270 and keeps an Overweight rating on the shares. The company’s Q1 print and commentary made a bioprocessing return to normal growth in 2023 unlikely, says the firm. "The sentiment on Tools just got worse," writes the analyst.